As CGRP-targeted therapies move into wider use, new data are beginning to clarify their role in special populations, the value of switching agents when one fails, and their long-term vascular safety.
The approval of medicines called CGRP antagonists has led to big changes in how migraine is managed. These medicines work in a different way than older medicines to treat or prevent migraine. The ...
Migraine is a chronic disease that affects 12 percent of the general population. In addition to severe, debilitating headache, patients with migraines may experience nausea, vomiting, and sensitivity ...
New guidelines recommend a sequential treatment approach for episodic migraine, starting with beta-blockers, antiseizure medications, SNRIs, and TCAs. CGRP antagonists and monoclonal antibodies are ...
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today that the U.S. Food and ...
The first three calcitonin gene-related peptide (CGRP) inhibitors approved for prevention of migraine displayed a reassuring safety profile in real-world clinical practice during the first 6 months ...
Hosted on MSN
Nurtec ODT: FDA approved as the only migraine medication for prevention and acute treatment
Keeping track of your migraine medications can be frustrating, especially if you use daily preventive drugs alongside your acute or “as-needed” treatments. Did you take the preventive medication on ...
PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results